DiHeSys and Harro Höfliger plan to contribute to the personalized therapy of the future by producing medicines using 2D and 3D printers.
A precisely coordinated therapy with the optimal amount of active ingredient for each individual patient - this is the vision of DiHeSys Digital Health Systems GmbH, based in Ulm. As part of a strategic cooperation, the company is now developing GMP-compliant dosing systems for 2D and 3D printing together with Harro Höfliger in order to be able to produce personalized thin films and tablets.
Combining Harro Höfliger's expertise in machine technology and DiHeSys' know-how in the field of pharmaceutical digital printing and formulation technology should enable doctors and pharmacists to prescribe and produce individualized medicines. Taking into account personal patient data such as weight, height and lifestyle habits, medicines could in future be produced directly in the pharmacy using the jointly developed pharmaceutical printers.
"The collaboration creates synergies that represent clear added value for our customers in the healthcare markets," says Dr. Markus Dachtler, CEO of DiHeSys. "This enables us to offer pharmaceutical-quality digital drug printers, formulations and print cartridges containing active ingredients from a single source. This enables us to guarantee a safe, high-quality and precise supply of medicines."
Thomas Weller, CEO of Harro Höfliger, is certain that individualized therapy - especially in view of the advancing digitalization with ever larger amounts of treatment data - will play an increasing role in the healthcare system of the future: "With this cooperation, we are at the forefront of these developments and are making an important contribution to personalized therapies of the future."
Photo: ICS Ute Huber
Comentarios